Showing results (1-10 of 388) with videos related to
Sort By:
Pageof 39
Breast (Edinburgh, Scotland)|May 6, 2014
Cardiotoxicity of systemic agents used in breast cancerFelipe Ades, Dimitrios Zardavas, Ana Catarina Pinto, et al.Ecancermedicalscience|July 11, 2017
The past and future of breast cancer treatment-from the papyrus to individualised treatment approachesFelipe Ades, Konstantinos Tryfonidis, Dimitrios ZardavasAdvances in Therapy|October 25, 2011
Survival benefit of eribulin mesylate in heavily pretreated metastatic breast cancer: what next?Philippe Aftimos, Ahmad AwadaExpert Review of Anticancer Therapy|October 22, 2013
Clinical practice-changing trials: the HERA study paradigmDimitrios Zardavas, Felipe Ades, Evandro de AzambujaCurrent Opinion in Oncology|February 26, 2015
New generations of targeted therapies fighting the resistance in solid tumorsPhilippe Barthélémy, Philippe Aftimos, Ahmad AwadaCurrent Opinion in Oncology|July 19, 2016
Current-day precision oncology: from cancer prevention, screening, drug development, and treatment - have we fallen short of the promise?Gilberto Morgan, Philippe Aftimos, Ahmad AwadaCurrent Opinion in Oncology|March 14, 2012
Personalized management of patients with solid cancers: moving from patient characteristics to tumor biologyAhmad Awada, Anna M Vandone, Philippe AftimosExpert Opinion on Emerging Drugs|January 29, 2016
Emerging drugs targeting human epidermal growth factor receptor 2 (HER2) in the treatment of breast cancerGil Awada, Andrea Gombos, Philippe Aftimos, et al.Current Opinion in Oncology|April 9, 2014
Impact of tumor sequencing on the use of anticancer drugsFrançois Thomas, Christine Desmedt, Philippe Aftimos, et al.Plos One|March 15, 2017
Are life-saving anticancer drugs reaching all patients? Patterns and discrepancies of trastuzumab use in the European Union and the USAFelipe Ades, Christelle Senterre, Dimitrios Zardavas, et al.Pageof 39